Lapatinib 250 Mg Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 250 mg
Reference Brands: Herduo (India), Tykerb (USA/EU)
Category:
Oncology Cancer Care
Lapatinib is used in the treatment of breast cancer.
Lapatinib 250 mg Tablet is available in Tablets
and strengths such as 250 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lapatinib 250 mg Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lapatinib 250 mg Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lapatinib is an oral anticancer medicine used in the treatment of certain types of breast cancer, particularly HER2-positive advanced or metastatic breast cancer. It works as a targeted therapy that blocks specific proteins (HER2 and EGFR receptors) responsible for the growth and spread of cancer cells. Lapatinib is commonly prescribed in combination with other treatments such as capecitabine or letrozole to improve treatment effectiveness in patients whose disease has progressed after other therapies.
This medicine belongs to the class of tyrosine kinase inhibitors and plays an important role in modern oncology treatment strategies. It is typically used when cancer cells overexpress the HER2 receptor, helping slow tumor growth and disease progression. Lapatinib is available in tablet form and is widely used in oncology care across many countries, with the original brand developed by GlaxoSmithKline.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing